Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $202,163 | 91 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $129,708 | 56 | $0 (2024) |
| Shire North American Group Inc | $72,455 | 35 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,516 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($30,516) |
| 2023 | $18,844 | 8 | Takeda Pharmaceuticals U.S.A., Inc. ($18,844) |
| 2022 | $27,516 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($27,516) |
| 2021 | $26,516 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($26,516) |
| 2020 | $26,316 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($26,316) |
| 2019 | $25,316 | 12 | Shire North American Group Inc ($25,316) |
| 2018 | $23,023 | 11 | Shire North American Group Inc ($23,023) |
| 2017 | $24,116 | 12 | Shire North American Group Inc ($24,116) |
All Payment Transactions
91 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 08/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 07/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 05/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 04/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 03/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 02/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 01/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 12/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 11/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,543.00 | General |
| 10/09/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 09/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 07/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 06/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 04/07/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 02/08/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 12/07/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 11/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 10/05/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 09/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
| 08/17/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,293.00 | General |
About Dr. Kimberly Blakeslee, D.O
Dr. Kimberly Blakeslee, D.O is a Family Medicine healthcare provider based in Missoula, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659327609.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kimberly Blakeslee, D.O has received a total of $202,163 in payments from pharmaceutical and medical device companies, with $30,516 received in 2024. These payments were reported across 91 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($202,163).
Practice Information
- Specialty Family Medicine
- Location Missoula, MT
- Active Since 05/25/2006
- Last Updated 10/02/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1659327609
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Missoula
Aubrey Remmers, M.d, M.D
Family Medicine — Payments: $103,185
Joey Banks, Md, MD
Family Medicine — Payments: $29,680
Dr. Denise Kelley, Md, MD
Family Medicine — Payments: $8,235
Timothy Mccue, M.d, M.D
Family Medicine — Payments: $3,583
Dr. Eric Ravitz, D.o, D.O
Family Medicine — Payments: $2,717
Dr. Courtney Hathaway, Md, MD
Family Medicine — Payments: $2,649